Toll Free: 1-888-928-9744

Rhabdomyosarcoma - Pipeline Review, H1 2015

Published: Mar, 2015 | Pages: 87 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Rhabdomyosarcoma - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Rhabdomyosarcoma - Pipeline Review, H1 2015’, provides an overview of the Rhabdomyosarcoma’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Rhabdomyosarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rhabdomyosarcoma and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Rhabdomyosarcoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Rhabdomyosarcoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Rhabdomyosarcoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Rhabdomyosarcoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Rhabdomyosarcoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Rhabdomyosarcoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Rhabdomyosarcoma Overview 6
Therapeutics Development 7
Pipeline Products for Rhabdomyosarcoma - Overview 7
Pipeline Products for Rhabdomyosarcoma - Comparative Analysis 8
Rhabdomyosarcoma - Therapeutics under Development by Companies 9
Rhabdomyosarcoma - Therapeutics under Investigation by Universities/Institutes 10
Rhabdomyosarcoma - Pipeline Products Glance 11
Clinical Stage Products 11
Rhabdomyosarcoma - Products under Development by Companies 12
Rhabdomyosarcoma - Products under Investigation by Universities/Institutes 13
Rhabdomyosarcoma - Companies Involved in Therapeutics Development 14
Bellicum Pharmaceuticals, Inc. 14
Boehringer Ingelheim GmbH 15
Celgene Corporation 16
Eisai Co., Ltd. 17
GlaxoSmithKline plc 18
Merrimack Pharmaceuticals, Inc. 19
Neotropix, Inc. 20
Novartis AG 21
Rhabdomyosarcoma - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Target 23
Assessment by Mechanism of Action 25
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Drug Profiles 31
afatinib - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Cell Therapy for GD2 Expressing Solid Tumors - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
celyvir - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Dendritic Cell Therapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
E-7438 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
everolimus - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
irinotecan sucrosofate liposomal - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
NTX-010 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
paclitaxel albumin bound - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
pazopanib hydrochloride - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Rhabdomyosarcoma - Recent Pipeline Updates 58
Rhabdomyosarcoma - Dormant Projects 84
Rhabdomyosarcoma - Discontinued Products 85
Appendix 86
Methodology 86
Coverage 86
Secondary Research 86
Primary Research 86
Expert Panel Validation 86
Contact Us 86
Disclaimer 87
List of Tables

Number of Products under Development for Rhabdomyosarcoma, H1 2015 7
Number of Products under Development for Rhabdomyosarcoma - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Number of Products under Investigation by Universities/Institutes, H1 2015 10
Comparative Analysis by Clinical Stage Development, H1 2015 11
Products under Development by Companies, H1 2015 12
Products under Investigation by Universities/Institutes, H1 2015 13
Rhabdomyosarcoma - Pipeline by Bellicum Pharmaceuticals, Inc., H1 2015 14
Rhabdomyosarcoma - Pipeline by Boehringer Ingelheim GmbH, H1 2015 15
Rhabdomyosarcoma - Pipeline by Celgene Corporation, H1 2015 16
Rhabdomyosarcoma - Pipeline by Eisai Co., Ltd., H1 2015 17
Rhabdomyosarcoma - Pipeline by GlaxoSmithKline plc, H1 2015 18
Rhabdomyosarcoma - Pipeline by Merrimack Pharmaceuticals, Inc., H1 2015 19
Rhabdomyosarcoma - Pipeline by Neotropix, Inc., H1 2015 20
Rhabdomyosarcoma - Pipeline by Novartis AG, H1 2015 21
Assessment by Monotherapy Products, H1 2015 22
Number of Products by Stage and Target, H1 2015 24
Number of Products by Stage and Mechanism of Action, H1 2015 26
Number of Products by Stage and Route of Administration, H1 2015 28
Number of Products by Stage and Molecule Type, H1 2015 30
Rhabdomyosarcoma Therapeutics - Recent Pipeline Updates, H1 2015 58
Rhabdomyosarcoma - Dormant Projects, H1 2015 84
Rhabdomyosarcoma - Discontinued Products, H1 2015 85 



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify